甲磺酸倍他司汀联合依达拉奉右莰醇治疗后循环缺血性眩晕患者的效果分析

Effect Analysis of Betahistine Mesylate Combined with Edaravone Dextrocamphenol in the Treatment of Patients with Post-Circulation Ischemic Vertigo

目的:分析甲磺酸倍他司汀和依达拉奉右莰醇联合治疗后循环缺血性眩晕患者的效果。方法:回顾性分析2022年1月—2023年12月赣州市赣县区人民医院收治的80例后循环缺血性眩晕患者的临床资料,根据用药不同分为对照组和研究组,各40例。对照组采用甲磺酸倍他司汀治疗,研究组在对照组基础上联合依达拉奉右莰醇治疗,比较两组的治疗效果、脑血流动力学、神经功能及不良反应发生情况。结果:研究组的治疗总有效率95.00%高于对照组的77.50%,差异有统计学意义(P<0.05);治疗后,两组最小血流量和最小血流速度均高于治疗前,且研究组的最小血流量和最小血流速度均高于对照组,差异均有统计学意义(P<0.05);治疗后,两组美国国立卫生研究院卒中量表(NIHSS)评分均低于治疗前,蒙特利尔认知评估量表(MOCA)评分均高于治疗前,且研究组NIHSS评分低于对照组,MOCA评分高于对照组,差异均有统计学意义(P<0.05);研究组不良反应发生率17.50%和对照组的12.50%比较,差异无统计学意义(P>0.05)。结论:甲磺酸倍他司汀联合依达拉奉右莰醇治疗后循环缺血性眩晕患者有助于提高治疗效果,改善脑血流动力学参数水平和脑神经功能,且安全性良好。

Objective:To analyze the effect of Betahistine Mesylate and Edaravone Dextrocamphenol in the treatment of patients with post-circulation ischemic vertigo.Methods:Data of 80 patients with post-circulation ischemic vertigo treated in Ganxian District People’s Hospital of Ganzhou City from January 2022 to December 2023 were retrospectively analyzed,and were divided into a control group and a study group with 40 cases each according to different drug use.The control group was treated with Betahistine Mesylate,and the study group was treated with Edaravone Dexcamphorol on the basis of the control group.The therapeutic effect,cerebral hemodynamics,neurological function and occurrence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 95.00%,higher than 77.50%of the control group,the difference was statistically significant(P<0.05);after treatment,the minimum blood flow in both groups was higher than before treatment,and the study group was higher than the control group.The minimum blood flow velocity in both groups was faster than before treatment,and the study group was faster than the control group,with statistical significance(P<0.05);after treatment,the National Institutes of Health Stroke Scale(NIHSS)scores of both groups were lower than those before treatment,and the Montreal Cognitive Assessment Scale(MOCA)scores were higher than those before treatment,and the NIHSS score of the study group was lower than that of the control group,and the MOCA score was higher than that of the control group,with statistical significance(P<0.05);there was no significant difference between the incidence of adverse reactions 17.50%in the study group and 12.50%in the control group(P>0.05).Conclusion:Betahistine Mesylate combined with Edaravone Dextrocamphorol in the treatment of patients with post-circulation ischemic vertigo can improve the therapeutic effect,improve the level of cerebral hemodynamic parameters and cerebral nerve function,and does not significantly increase the adverse reactions.